Supplemental Online Content

Loomans-Kropp HA, Pinsky P, Umar A. Evaluation of aspirin use with cancer incidence and survival among older adults in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. *JAMA Netw Open*. 2021;4(1):e2032072. doi:10.1001/jamanetworkopen.2020.32072

- eTable 1. Unadjusted Hazard Ratios and 95% Cls of Aspirin Use and Risk of Cancer
- **eTable 2.** Covariates Included in the Multivariable Cox Proportional Hazards of Cancer Risk (Figure 2), Comparing Aspirin Use Less Than 3 Times/Week and at Least 3 Times/Week
- **eTable 3.** Unadjusted Hazard Ratios and 95% CIs of Aspirin Use and Risk of Cancer-Specific Death
- **eTable 4.** Covariates Included in the Multivariable Cox Proportional Hazards of Risk of Cancer-Specific Death (Figure 4), Comparing Aspirin Use Less Than 3 Times/Week and at Least 3 Times/Week

This supplemental material has been provided by the authors to give readers additional information about their work.

eTable 1. Unadjusted Hazard Ratios and 95% CIs of Aspirin Use and Risk of Cancer

	Reported aspirin us	e yes ^a	Reported aspirin use frequency ≥3 times/week ^b		
Cancer site	HR (95% CI)	HR (95% CI) p-value		<i>p</i> -value	
Bladder cancer	1.18 (1.08, 1.30)	<0.001	1.25 (1.13, 1.37)	<0.001	
Breast cancer ^c	1.00 (0.94, 1.06)	0.91	1.00 (0.94, 1.06)	0.92	
Esophageal cancer	1.07 (0.86, 1.33)	0.53	1.14 (0.92, 1.42)	0.22	
Gastric cancer	0.92 (0.76, 1.13)	0.43	0.95 (0.78, 1.16)	0.62	
Pancreatic cancer	0.94 (0.82, 1.07)	0.34	1.00 (0.88, 1.15)	0.97	
Uterine cancer ^c	0.95 (0.82, 1.10)	0.49	0.92 (0.79, 1.07)	0.29	

^aReference: no aspirin use^c ^bReference: <3 times/month

Abbreviations: PLCO = Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; HR = hazard ratio; 95% CI = 95% confidence interval

^cModels for breast and uterine cancer included female participants only

eTable 2. Covariates Included in the Multivariable Cox Proportional Hazards of Cancer Risk (Figure 2), Comparing Aspirin Use Less Than 3 Times/Week and at Least 3 Times/Week

-	Cancer Type					
-	Bladder (N=1751)	Breast (N=4552)	Esophageal (N=332)	Gastric (N=397)	Pancreatic (N=878)	Uterine (N=716)
Variable	Adjusted HR (95% CI)					
Sex						
Male Female	1.0 (ref) 0.27 (0.24, 0.31)		1.0 (ref) 0.21 (0.16, 0.29)	1.0 (ref) 0.42 (0.33, 0.52)	1.0 (ref) 0.86 (0.74, 0.98)	
Race						
White, non-Hispanic Black, non-Hispanic Other	1.0 (ref) 0.54 (0.40, 0.73) 0.57 (0.45, 0.72)	1.0 (ref) 0.87 (0.76, 1.00) 0.86 (0.76, 0.98)	1.0 (ref) 0.62 (0.33, 1.17) 0.80 (0.51, 1.27)	1.0 (ref) 2.19 (1.54, 3.12) 2.17 (1.63, 2.89)	1.0 (ref) 1.31 (1.00, 1.73) 1.27 (1.00, 1.61)	1.0 (ref) 0.77 (0.53, 1.10) 0.84 (0.61, 1.16)
Smoking status						
Never smoker Current smoker Former smoker	1.0 (ref) 3.09 (2.64, 3.62) 1.90 (1.70, 2.13)	1.0 (ref) 0.92 (0.82, 1.04) 1.12 (1.05, 1.26)	1.0 (ref) 3.73 (2.62, 5.32) 1.93 (1.47, 2.52)	1.0 (ref) 1.75 (1.25, 2.46) 1.31 (1.05, 1.63)	1.0 (ref) 1.90 (1.54, 2.36) 0.97 (0.84, 1.12)	1.0 (ref) 0.68 (0.48, 0.95) 0.91 (0.77, 1.06)
Randomization arm						
Intervention Control	1.0 (ref) 1.04 (0.95, 1.14)	1.0 (ref) 0.96 (0.93, 1.05)	1.0 (ref) 1.34 (1.08, 1.67)	1.0 (ref) 1.01 (0.83, 1.23)	1.0 (ref) 0.90 (0.79, 1.03)	1.0 (ref) 1.10 (0.95, 1.28)
History of heart attack						
No Yes	1.0 (ref) 1.16 (1.01, 1.35)	1.0 (ref) 0.98 (0.85, 1.13)	1.0 (ref) 1.28 (0.93, 1.76)	1.0 (ref) 1.19 (0.87, 1.62)	1.0 (ref) 1.26 (1.01, 1.56)	1.0 (ref) 0.99 (0.69, 1.40)
History of stroke						
No Yes	1.0 (ref) 1.18 (0.95, 1.48)	1.0 (ref) 0.96 (0.81, 1.15)	1.0 (ref) 0.83 (0.46, 1.49)	1.0 (ref) 1.40 (0.90, 2.16)	1.0 (ref) 0.92 (0.65, 1.31)	1.0 (ref) 0.82 (0.51, 1.32)
History of hypertension						
No Yes	1.0 (ref) 1.04 (0.94, 1.15)	1.0 (ref) 1.06 (1.00, 1.13)	1.0 (ref) 1.41 (1.13, 1.78)	1.0 (ref) 1.12 (0.91, 1.37)	1.0 (ref) 1.16 (1.01, 1.33)	1.0 (ref) 1.08 (0.92, 1.26)
History of diabetes						
No Yes	1.0 (ref) 1.30 (1.13, 1.50)	1.0 (ref) 1.11 (1.00, 1.23)	1.0 (ref) 1.15 (0.83, 1.60)	1.0 (ref) 1.64 (1.25, 2.14)	1.0 (ref) 1.70 (1.41, 2.04)	1.0 (ref) 1.62 (1.28, 2.05)

eTable 3. Unadjusted Hazard Ratios and 95% CIs of Aspirin Use and Risk of Cancer-Specific Death

	Reported aspirin use yes ^a		Reported aspirin use frequency ≥3 times/week ^b		
Cancer site	HR (95% CI)	HR (95% CI) p-value		<i>p</i> -value	
Bladder cancer	0.80 (0.63, 1.03)	0.08	0.76 (0.59, 0.98)	0.03	
Breast cancer ^c	0.83 (0.67,1.03)	0.09	0.80 (0.64, 1.02)	0.07	
Esophageal cancer	1.12 (0.86, 1.46)	0.39	1.11 (0.86, 1.44)	0.42	
Gastric cancer	0.96 (0.74, 1.24)	0.77	0.91 (0.70, 1.18)	0.49	
Pancreatic cancer	0.93 (0.80, 1.07)	0.29	0.93 (0.80, 1.07)	0.31	
Uterine cancer ^c	1.20 (0.82, 1.76)	0.35	0.86 (0.57, 1.30)	0.48	

^aReference: no aspirin use

Abbreviations: PLCO = Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; HR = hazard ratio; 95% CI = 95% confidence interval

^bReference: <3 times/month

^cModels for breast and uterine cancer included female participants only

eTable 4. Covariates Included in the Multivariable Cox Proportional Hazards of Risk of Cancer-Specific Death (Figure 4), Comparing Aspirin Use Less Than 3 Times/Week and at Least 3 Times/Week

-	Cancer Type					
-	Bladder (N=249)	Breast (N=333)	Esophageal (N=230)	Gastric (N=234)	Pancreatic (N=730)	Uterine (N=106)
Variable	Adjusted HR (95% CI)	Adjusted HR (95% CI)	Adjusted HR (95% CI)	Adjusted HR (95% CI)	Adjusted HR (95% CI)	Adjusted HR (95% CI)
Age at diagnosis	1.06 (1.04, 1.08)	1.04 (1.02, 1.05)	1.03 (0.79, 1.36)	1.02 (1.00, 1.04)	1.03 (1.01, 1.04)	1.03 (1.00, 1.05)
Sex						
Male Female	1.0 (ref) 0.88 (0.64, 1.22)		1.0 (ref) 0.90 (0.63, 1.28)	1.0 (ref) 0.99 (0.74, 1.32)	1.0 (ref) 0.94 (0.81, 1.09)	
Race						
White, non-Hispanic Black, non-Hispanic Other	1.0 (ref) 1.46 (0.71, 2.99)	1.0 (ref) 1.89 (1.30, 2.75)	1.0 (ref) 0.96 (0.48, 1.92)	1.0 (ref) 0.61 (0.37, 1.00)	1.0 (ref) 0.87 (0.63, 1.19)	1.0 (ref) 1.1 (0.82, 3.57)
	0.76 (0.39, 1.48)	0.67 (0.39, 1.15)	1.13 (0.68, 1.89)	0.58 (0.39, 0.86)	1.07 (0.83, 1.38)	0.32 (0.08, 1.31)
Smoking status Never smoker Current smoker	1.0 (ref) 1.38 (0.67, 2.83)	1.0 (ref) 1.77 (1.19, 2.64)	1.0 (ref) 0.94 (0.41, 2.17)	1.0 (ref) 1.95 (0.92, 4.13)	1.0 (ref) 1.24 (0.97, 1.57)	1.0 (ref) 0.89 (0.32, 2.48
Former smoker	0.65 (0.33, 1.27)	1.17 (0.93, 1.47)	0.84 (0.52, 1.38)	0.92 (0.58, 1.45)	0.94 (0.80, 1.10)	0.90 (0.59, 1.37
Randomization arm Intervention Control	1.0 (ref) 1.05 (0.82, 1.34)	1.0 (ref) 1.02 (00.82, 1.27)	1.0 (ref) 1.15 (0.88, 1.50)	1.0 (ref) 0.84 (0.65, 1.10)	1.0 (ref) 1.04 (0.89, 1.20)	1.0 (ref) 1.18 (0.80, 1.73
History of heart attack						
No Yes	1.0 (ref) 1.38 (0.97, 1.96)	1.0 (ref) 1.24 (0.79, 1.95)	1.0 (ref) 1.22 (0.84, 1.76)	1.0 (ref) 1.18 (0.79, 1.76)	1.0 (ref) 1.12 (0.87, 1.42)	1.0 (ref) 1.16 (0.48, 2.78
History of stroke						
No Yes	1.0 (ref) 1.21 (0.71, 2.07)	1.0 (ref) 1.10 (0.60, 2.03)	1.0 (ref) 1.89 (1.01, 3.54)	1.0 (ref) 0.95 (0.53, 1.71)	1.0 (ref) 1.15 (0.78, 1.68)	1.0 (ref) 0.87 (0.27, 2.79
History of hypertension						
No Yes	1.0 (ref) 1.08 (0.83, 1.40)	1.0 (ref) 1.01 (0.81, 1.27)	1.0 (ref) 1.08 (2, 1.42)	1.0 (ref) 1.20 (0.92, 1.58)	1.0 (ref) 1.02 (0.88, 1.19)	1.0 (ref) 1.54 (1.02, 2.33
History of diabetes						
No Yes	1.0 (ref) 0.99 (0.68, 1.44)	1.0 (ref) 1.42 (0.99, 2.03)	1.0 (ref) 1.20 (0.81, 1.78)	1.0 (ref) 1.04 (0.72, 1.50)	1.0 (ref) 1.11 (0.91, 1.36)	1.0 (ref) 1.22 (70, 2.13)

^{© 2021} Loomans-Kropp HA et al. JAMA Network Open.